DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime–boost immunization protocol, including a HIV-1 DNA gp160/rev pla...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2007-08, Vol.25 (32), p.5968-5977 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5977 |
|---|---|
| container_issue | 32 |
| container_start_page | 5968 |
| container_title | Vaccine |
| container_volume | 25 |
| creator | Buonaguro, L Devito, C Tornesello, M.L Schröder, U Wahren, B Hinkula, J Buonaguro, F.M |
| description | Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime–boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2–V5 region in the heterologous prime–boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA–VLP heterologous prime–boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3. |
| doi_str_mv | 10.1016/j.vaccine.2007.05.052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_569226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X07006354</els_id><sourcerecordid>19744764</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-af68593b68670b33f652e93d276f53cd3119bc45e8a49ed75ebd1df0d9d935903</originalsourceid><addsrcrecordid>eNqFkt-K1DAUxoso7rj6CEpB9MqO-dOkzY0y7Kq7MKigDt6FNDndzWybjkk7y-yV7-C1L-eTmM4MDizIQiAh-eXLOV--JHmK0RQjzF8vp2ultXUwJQgVU8TiIPeSCS4LmhGGy_vJBBGeZzlG34-SRyEsEUKMYvEwOcIFJ4JyNkl-n36c_fn5azH_nK68bSGuq64LfWpd71XmVFBNatt2cPZG9bZz8cAMGkKqoWmGRvlUOZNeDm3nI6lcb7Oz80WG07AJPbRWb8_bQXcHpX6TXtv-MtW-CyHTjTKQOhjig429se4iVbq364g9Th7UqgnwZD8fJ9_ev_t6cpbNP304P5nNMx376DNV85IJWvGSF6iitOaMgKCGFLxmVBuKsah0zqBUuQBTMKgMNjUywgjKBKLHSbbTDdewGio5WqH8RnbKyv3WVVyBZFwQwiP_6r_8qV3MZOcvZGMHSUvG84i_3OEr3_0YIPSytWH0TznohiALVKBYBb4TxKLI82Kr-PwWuOwG76JHErPYkSCYjRTbUVujPdT_CsVIjimSS7lPkRxTJBGLg8R7z_bqQ9WCOdzaxyYCL_aAClo1tVdO23DgSpELhkef3u44iJ-3tuBl0BacBmM96F6azt5ZyptbCrqxzsZHr2AD4dC1DEQi-WWM_Jj46CjiNHrwFwSZAgM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559092154</pqid></control><display><type>article</type><title>DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>SWEPUB Freely available online</source><creator>Buonaguro, L ; Devito, C ; Tornesello, M.L ; Schröder, U ; Wahren, B ; Hinkula, J ; Buonaguro, F.M</creator><creatorcontrib>Buonaguro, L ; Devito, C ; Tornesello, M.L ; Schröder, U ; Wahren, B ; Hinkula, J ; Buonaguro, F.M</creatorcontrib><description>Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime–boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2–V5 region in the heterologous prime–boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA–VLP heterologous prime–boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2007.05.052</identifier><identifier>PMID: 17629365</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Acquired immune deficiency syndrome ; Administration, Intranasal ; AIDS ; AIDS Vaccines - administration & dosage ; AIDS Vaccines - immunology ; Allergy and Immunology ; Animals ; Antigens ; Applied microbiology ; Biological and medical sciences ; Deoxyribonucleic acid ; DNA ; Epitope Mapping ; Epitopes, B-Lymphocyte - immunology ; Female ; Fundamental and applied biological sciences. Psychology ; HIV Antibodies - blood ; HIV Antibodies - immunology ; HIV Envelope Protein gp160 - immunology ; HIV-1 ; HIV-1 - classification ; HIV-1 - immunology ; Human immunodeficiency virus 1 ; Humoral immunity ; Immune response ; Immune system ; Immunity, Cellular - immunology ; Immunity, Mucosal - immunology ; Immunization ; Immunization, Secondary ; Immunogenicity ; Immunoglobulin G - blood ; Infections ; Laboratories ; Lymph Nodes - cytology ; Lymph Nodes - immunology ; MEDICIN ; MEDICINE ; Mice ; Microbiology ; Miscellaneous ; Mucosal adjuvants ; Mucosal response ; Prime–boost approach ; Proteins ; Spleen - cytology ; Spleen - immunology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, DNA - administration & dosage ; Vaccines, DNA - immunology ; Viral infections ; Virology ; Virus-like particles (VLP)</subject><ispartof>Vaccine, 2007-08, Vol.25 (32), p.5968-5977</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Aug 10, 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-af68593b68670b33f652e93d276f53cd3119bc45e8a49ed75ebd1df0d9d935903</citedby><cites>FETCH-LOGICAL-c629t-af68593b68670b33f652e93d276f53cd3119bc45e8a49ed75ebd1df0d9d935903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X07006354$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18949516$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17629365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-38564$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:115758827$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Buonaguro, L</creatorcontrib><creatorcontrib>Devito, C</creatorcontrib><creatorcontrib>Tornesello, M.L</creatorcontrib><creatorcontrib>Schröder, U</creatorcontrib><creatorcontrib>Wahren, B</creatorcontrib><creatorcontrib>Hinkula, J</creatorcontrib><creatorcontrib>Buonaguro, F.M</creatorcontrib><title>DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime–boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2–V5 region in the heterologous prime–boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA–VLP heterologous prime–boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3.</description><subject>Acquired immune deficiency syndrome</subject><subject>Administration, Intranasal</subject><subject>AIDS</subject><subject>AIDS Vaccines - administration & dosage</subject><subject>AIDS Vaccines - immunology</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epitope Mapping</subject><subject>Epitopes, B-Lymphocyte - immunology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HIV Antibodies - blood</subject><subject>HIV Antibodies - immunology</subject><subject>HIV Envelope Protein gp160 - immunology</subject><subject>HIV-1</subject><subject>HIV-1 - classification</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus 1</subject><subject>Humoral immunity</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity, Cellular - immunology</subject><subject>Immunity, Mucosal - immunology</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G - blood</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Lymph Nodes - cytology</subject><subject>Lymph Nodes - immunology</subject><subject>MEDICIN</subject><subject>MEDICINE</subject><subject>Mice</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Mucosal adjuvants</subject><subject>Mucosal response</subject><subject>Prime–boost approach</subject><subject>Proteins</subject><subject>Spleen - cytology</subject><subject>Spleen - immunology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, DNA - administration & dosage</subject><subject>Vaccines, DNA - immunology</subject><subject>Viral infections</subject><subject>Virology</subject><subject>Virus-like particles (VLP)</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>D8T</sourceid><recordid>eNqFkt-K1DAUxoso7rj6CEpB9MqO-dOkzY0y7Kq7MKigDt6FNDndzWybjkk7y-yV7-C1L-eTmM4MDizIQiAh-eXLOV--JHmK0RQjzF8vp2ultXUwJQgVU8TiIPeSCS4LmhGGy_vJBBGeZzlG34-SRyEsEUKMYvEwOcIFJ4JyNkl-n36c_fn5azH_nK68bSGuq64LfWpd71XmVFBNatt2cPZG9bZz8cAMGkKqoWmGRvlUOZNeDm3nI6lcb7Oz80WG07AJPbRWb8_bQXcHpX6TXtv-MtW-CyHTjTKQOhjig429se4iVbq364g9Th7UqgnwZD8fJ9_ev_t6cpbNP304P5nNMx376DNV85IJWvGSF6iitOaMgKCGFLxmVBuKsah0zqBUuQBTMKgMNjUywgjKBKLHSbbTDdewGio5WqH8RnbKyv3WVVyBZFwQwiP_6r_8qV3MZOcvZGMHSUvG84i_3OEr3_0YIPSytWH0TznohiALVKBYBb4TxKLI82Kr-PwWuOwG76JHErPYkSCYjRTbUVujPdT_CsVIjimSS7lPkRxTJBGLg8R7z_bqQ9WCOdzaxyYCL_aAClo1tVdO23DgSpELhkef3u44iJ-3tuBl0BacBmM96F6azt5ZyptbCrqxzsZHr2AD4dC1DEQi-WWM_Jj46CjiNHrwFwSZAgM</recordid><startdate>20070810</startdate><enddate>20070810</enddate><creator>Buonaguro, L</creator><creator>Devito, C</creator><creator>Tornesello, M.L</creator><creator>Schröder, U</creator><creator>Wahren, B</creator><creator>Hinkula, J</creator><creator>Buonaguro, F.M</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>ABXSW</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DG8</scope><scope>ZZAVC</scope></search><sort><creationdate>20070810</creationdate><title>DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity</title><author>Buonaguro, L ; Devito, C ; Tornesello, M.L ; Schröder, U ; Wahren, B ; Hinkula, J ; Buonaguro, F.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-af68593b68670b33f652e93d276f53cd3119bc45e8a49ed75ebd1df0d9d935903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Administration, Intranasal</topic><topic>AIDS</topic><topic>AIDS Vaccines - administration & dosage</topic><topic>AIDS Vaccines - immunology</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epitope Mapping</topic><topic>Epitopes, B-Lymphocyte - immunology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HIV Antibodies - blood</topic><topic>HIV Antibodies - immunology</topic><topic>HIV Envelope Protein gp160 - immunology</topic><topic>HIV-1</topic><topic>HIV-1 - classification</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus 1</topic><topic>Humoral immunity</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity, Cellular - immunology</topic><topic>Immunity, Mucosal - immunology</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G - blood</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Lymph Nodes - cytology</topic><topic>Lymph Nodes - immunology</topic><topic>MEDICIN</topic><topic>MEDICINE</topic><topic>Mice</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Mucosal adjuvants</topic><topic>Mucosal response</topic><topic>Prime–boost approach</topic><topic>Proteins</topic><topic>Spleen - cytology</topic><topic>Spleen - immunology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, DNA - administration & dosage</topic><topic>Vaccines, DNA - immunology</topic><topic>Viral infections</topic><topic>Virology</topic><topic>Virus-like particles (VLP)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Buonaguro, L</creatorcontrib><creatorcontrib>Devito, C</creatorcontrib><creatorcontrib>Tornesello, M.L</creatorcontrib><creatorcontrib>Schröder, U</creatorcontrib><creatorcontrib>Wahren, B</creatorcontrib><creatorcontrib>Hinkula, J</creatorcontrib><creatorcontrib>Buonaguro, F.M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SWEPUB Linköpings universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Linköpings universitet</collection><collection>SwePub Articles full text</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Buonaguro, L</au><au>Devito, C</au><au>Tornesello, M.L</au><au>Schröder, U</au><au>Wahren, B</au><au>Hinkula, J</au><au>Buonaguro, F.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2007-08-10</date><risdate>2007</risdate><volume>25</volume><issue>32</issue><spage>5968</spage><epage>5977</epage><pages>5968-5977</pages><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime–boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2–V5 region in the heterologous prime–boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA–VLP heterologous prime–boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17629365</pmid><doi>10.1016/j.vaccine.2007.05.052</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2007-08, Vol.25 (32), p.5968-5977 |
| issn | 0264-410X 1873-2518 1873-2518 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_569226 |
| source | MEDLINE; Elsevier ScienceDirect Journals; SWEPUB Freely available online |
| subjects | Acquired immune deficiency syndrome Administration, Intranasal AIDS AIDS Vaccines - administration & dosage AIDS Vaccines - immunology Allergy and Immunology Animals Antigens Applied microbiology Biological and medical sciences Deoxyribonucleic acid DNA Epitope Mapping Epitopes, B-Lymphocyte - immunology Female Fundamental and applied biological sciences. Psychology HIV Antibodies - blood HIV Antibodies - immunology HIV Envelope Protein gp160 - immunology HIV-1 HIV-1 - classification HIV-1 - immunology Human immunodeficiency virus 1 Humoral immunity Immune response Immune system Immunity, Cellular - immunology Immunity, Mucosal - immunology Immunization Immunization, Secondary Immunogenicity Immunoglobulin G - blood Infections Laboratories Lymph Nodes - cytology Lymph Nodes - immunology MEDICIN MEDICINE Mice Microbiology Miscellaneous Mucosal adjuvants Mucosal response Prime–boost approach Proteins Spleen - cytology Spleen - immunology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - administration & dosage Vaccines, DNA - immunology Viral infections Virology Virus-like particles (VLP) |
| title | DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A21%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%E2%80%93VLP%20prime%E2%80%93boost%20intra-nasal%20immunization%20induces%20cellular%20and%20humoral%20anti-HIV-1%20systemic%20and%20mucosal%20immunity%20with%20cross-clade%20neutralizing%20activity&rft.jtitle=Vaccine&rft.au=Buonaguro,%20L&rft.date=2007-08-10&rft.volume=25&rft.issue=32&rft.spage=5968&rft.epage=5977&rft.pages=5968-5977&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2007.05.052&rft_dat=%3Cproquest_swepu%3E19744764%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559092154&rft_id=info:pmid/17629365&rft_els_id=1_s2_0_S0264410X07006354&rfr_iscdi=true |